- Home
- WPP vs LEGN Comparison
WPP vs LEGN Comparison
Compare WPP & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WPP | LEGN |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | WPP | LEGN |
|---|---|---|
| Price | $22.61 | $22.53 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $69.58 |
| AVG Volume (30 Days) | 518.8K | ★ 2.5M |
| Earning Date | 02-26-2026 | 11-12-2025 |
| Dividend Yield | ★ 9.03% | N/A |
| EPS Growth | ★ 86.47 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $19,423,208,660.00 | $909,045,000.00 |
| Revenue This Year | N/A | $68.52 |
| Revenue Next Year | N/A | $48.63 |
| P/E Ratio | $9.69 | ★ N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $17.47 | $20.21 |
| 52 Week High | $49.54 | $45.30 |
Technical Indicators
Market Signals| Indicator | WPP | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.54 | 41.82 |
| Support Level | $22.32 | $20.21 |
| Resistance Level | $23.92 | $22.07 |
| Average True Range (ATR) | 0.54 | 0.80 |
| MACD | 0.05 | 0.21 |
| Stochastic Oscillator | 36.21 | 67.16 |
Price Performance
Historical ComparisonAbout WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.